| SHARE-BASED COMPENSATION |
NOTE
7 - SHARE-BASED COMPENSATION:
| |
a. |
Overview of quarterly
period
The
Company's share-based compensation expenses amounted to a total of $542
and $58
in the six-month periods ended June 30, 2026 and 2025, respectively and $197
and $37
in the three-month periods ended June 30, 2026 and 2025, respectively. As of June 30, 2026, there are no shares that remain available
for future grants under the Company’s 2024 Equity Incentive Plan (the “2024 Plan”).
On
May 5, 2026, the Company’s extraordinary general meeting approved an increase to the number of ordinary shares added annually on
January 1 under the “evergreen” provision of Section 5(b)(i) of the 2024 Plan from (i) 5%
of the Company’s issued and outstanding ordinary shares, to (ii) such number of ordinary shares as yields a pool of ordinary shares
reserved under all equity incentive plans of the Company that constitutes, in the aggregate, 10%
of the issued and outstanding ordinary shares on a fully diluted basis. As a result of that increase under the “evergreen”
provision, 43,857
ordinary shares were immediately added to the pool of shares reserved for issuance under the 2024 Plan (in addition to the 15,632
ordinary shares already added to that pool as of January 1, 2026 under the prior “evergreen” provision).
All
of the foregoing ordinary shares added to the pool under the 2024 Plan pursuant to the “evergreen” provision effective as
of January 1, 2026 were allocated to grants to directors and employees during the six-month period ended June 30, 2026.
|
| |
b. |
Summary of options grants
and outstanding and exercisable options
Below
is a summary of the Company's share-based compensation activity and related information with respect to options granted to employees and
non-employees during the six-month period ended June 30, 2026: |
| |
|
|
|
|
Weighted-average
exercise price (in U.S. dollars) |
|
|
Weighted-
average remaining contractual term
(in
years) |
|
|
Aggregate
intrinsic
value
(in U.S. dollars) |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding
at January 1, 2026 |
|
|
627
|
|
|
|
2,417.71
|
|
|
|
8.39
|
|
|
|
-
|
|
|
Granted
|
|
|
4,273
|
|
|
|
16.50
|
|
|
|
9.63
|
|
|
|
-
|
|
|
Outstanding
at June 30, 2026 |
|
|
4,900
|
|
|
|
323.76
|
|
|
|
9.41
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable
at June 30, 2026 |
|
|
627
|
|
|
|
2,411.71
|
|
|
|
8.39
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested and
expected to vest at June 30, 2026 |
|
|
4,900
|
|
|
|
323.76
|
|
|
|
9.41
|
|
|
|
|
|
| |
|
In February 2026 and
2025, Silexion’s board of directors granted 4,273 options and 469 options, respectively,
to Silexion’s directors. |
| |
c. |
Summary of RSUs grants
to employees and non-employees
In
February 2025, Silexion’s board of directors approved granting 397 RSUs
to Silexion’s directors which vested and issued on February 2026.
In
the six months ended June 30, 2026, Silexion granted an aggregate of 63,873
RSUs, all of which were fully vested upon grant, and which immediately settled for 63,873 underlying ordinary shares, to its employees
and directors. |
| |
d. |
Overall share-based compensation
expense
The
share-based compensation expense by line item in the accompanying consolidated statements of operations is summarized as follows:
|
| |
|
|
|
|
Three
months ended
June
30 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development |
|
$
|
230
|
|
|
$
|
-
|
|
|
$
|
100
|
|
|
$
|
-
|
|
|
General and
administrative |
|
|
312
|
|
|
|
58
|
|
|
|
97
|
|
|
|
37
|
|
| |
|
|
542
|
|
|
|
58
|
|
|
|
197
|
|
|
|
37
|
|
|